Measles

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine

18100%

+ 56 programs with unclassified modality

Competitive Landscape

11 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

BiocorpFrance - Issoire

3 programs

MMR VaccinePhase 4Vaccine1 trial

MMR Bio-ManguinhosPhase 31 trial

Secondary Attack Rate Measles Vaccine In Second Situation Contacts Cases ConfirmedN/AVaccine1 trial

Active Trials

NCT05592756Completed2,964Est. Mar 2022

NCT01991899Completed1,560Est. Jul 2016

NCT01777529Completed240Est. Dec 2013

MSDIreland - Ballydine

17 programs

Comparator: M-M-RPhase 31 trial

Comparator: ProQuad™Phase 31 trial

M-M-R™II manufactured with recombinant Human AlbuminPhase 31 trial

MMRVPhase 31 trial

Measles, Mumps, Rubella and VaricellaPhase 31 trial

+12 more programs

Active Trials

NCT00962819Completed74Est. Dec 2012

NCT00986232Completed1,551Est. Sep 2000

NCT00109278Completed1,100Est. May 2005

+14 more trials

Sharp TherapeuticsPA - Pittsburgh

17 programs

Comparator: M-M-RPhase 3

Comparator: ProQuad™Phase 3

M-M-R™II manufactured with recombinant Human AlbuminPhase 3

MMRVPhase 3

Measles, Mumps, Rubella and VaricellaPhase 3

+12 more programs

ViiV HealthcareNC - Durham

8 programs

MMR Bio-ManguinhosPhase 3

MMRVNSPhase 3

MeMuRu-OKAPhase 3

Measles, Mumps, Rubella and ChickenpoxPhase 3

PriorixPhase 3

+3 more programs

Nordic PharmaFrance - Paris

1 program

MVA-mBN85BPhase 2

Allergy TherapeuticsUK - West Sussex

3 programs

MMR-IIPhase 1/21 trial

Measles vaccineN/AVaccine1 trial

Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella VaccinesN/A1 trial

Active Trials

NCT02058927Completed203Est. Feb 2012

NCT00138255Terminated32Est. Jun 2005

NCT00258726Terminated105Est. Jul 2007

Merck & Co.RAHWAY, NJ

12 programs

MMR vaccineN/AVaccine

Measles, Mumps, Rubella and VaricellaPHASE_2

V205C, measles, mumps, and rubella virus vaccine livePHASE_2Vaccine

measles, mumps, and rubella virus vaccine livePHASE_2Vaccine

M-M-R™II manufactured with recombinant Human AlbuminPHASE_3

+7 more programs

GSKLONDON, United Kingdom

8 programs

MMR vaccine / MMRV vaccineN/AVaccine1 trial

Priorix-TetraPHASE_21 trial

MMR Bio-ManguinhosPHASE_3

MMRVNSPHASE_31 trial

MeMuRu-OKAPHASE_31 trial

+3 more programs

Active Trials

NCT02712203Unknown5,808Est. Dec 2016

NCT00892775Completed501Est. Dec 2010

NCT07406360Not Yet Recruiting1,209Est. Jun 2028

+4 more trials

Novo NordiskBAGSVAERD DENMARK, Denmark

3 programs

Measles vaccinePHASE_4Vaccine1 trial

Active Trials

NCT00168571Completed1,960Est. Jan 2007

NCT00168558Completed5,879Est. Mar 2008

NCT00168545Completed400Est. Jan 2007

Bavarian NordicDenmark - Kvistgard

1 program

MVA-mBN85BPHASE_21 trial

Active Trials

NCT00891007Completed90Est. Aug 2010

SanofiPARIS, France

1 program

Inactivated Hep A vaccine; Attenuated Measles Mumps RubellaPHASE_4Vaccine1 trial

Active Trials

NCT00313950Completed470Est. Apr 2010

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

2028

BiocorpMMR Vaccine

SanofiInactivated Hep A vaccine; Attenuated Measles Mumps Rubella

Novo NordiskMeasles vaccine

GSKMMRVNS

BiocorpMMR Bio-Manguinhos

GSKPriorix

MSDMMRV

GSKPriorixTM

MSDMeasles, Mumps, Rubella and Varicella

MSDProQuad® manufactured with recombinant Human Albumin

MSDProQuad®

GSKMeMuRu-OKA

Showing 15 of 35 trials with date data

Clinical Trials (35)

Total enrollment: 49,651 patients across 35 trials

NCT01777529 BiocorpMMR Vaccine

Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations

Start: Oct 2012Est. completion: Dec 2013240 patients

Phase 4Completed

NCT00313950 SanofiInactivated Hep A vaccine; Attenuated Measles Mumps Rubella

Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine

Start: Sep 2006Est. completion: Apr 2010470 patients

Phase 4Completed

NCT00168545 Novo NordiskMeasles vaccine

Immunology of Non-specific Effects of Vaccine

Start: Jan 2006Est. completion: Jan 2007400 patients

Phase 4Completed

NCT00168558 Novo NordiskMeasles vaccine

Early Two-dose Measles Vaccination Trial

Start: Jul 2003Est. completion: Mar 20085,879 patients

Phase 4Completed

NCT00168571 Novo NordiskMeasles vaccine

Long-term Follow-up of Measles Antibodies

Start: Mar 2002Est. completion: Jan 20071,960 patients

Phase 4Completed

NCT07406360 GSKMMRVNS

A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age

Start: Apr 2026Est. completion: Jun 20281,209 patients

Phase 3Not Yet Recruiting

NCT01991899 BiocorpMMR Bio-Manguinhos

Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.

Start: Feb 2015Est. completion: Jul 20161,560 patients

Phase 3Completed

NCT01681992 GSKPriorix

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

Start: Oct 2012Est. completion: Aug 20154,538 patients

Phase 3Completed

NCT01536405 MSDMMRV

Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)

Start: Jun 2012Est. completion: Jan 20141,412 patients

Phase 3Completed

NCT00751348 GSKPriorixTM

Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136

Start: Oct 2008Est. completion: May 2010475 patients

Phase 3Completed

NCT00839917 MSDMeasles, Mumps, Rubella and Varicella

A Study of ProQuad™ in Healthy Children in Korea (V221-023)

Start: Feb 2008Est. completion: May 200830 patients

Phase 3Terminated

NCT00566527 MSDProQuad® manufactured with recombinant Human Albumin

Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)

Start: Nov 2007Est. completion: Dec 20081,620 patients

Phase 3Completed

NCT00560755 MSDProQuad®

Safety Study of ProQuad® rHA in Infants (V221-037)

Start: Oct 2007Est. completion: Nov 20083,388 patients

Phase 3Completed

NCT00402831 MSDProQuad®

ProQuad® Intramuscular vs Subcutaneous

Start: Oct 2006Est. completion: May 2007405 patients

Phase 3Completed

NCT00351923 GSKMeMuRu-OKA

Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes

Start: Mar 2006Est. completion: Dec 2006330 patients

Phase 3Completed

NCT00109343 MSDComparator: ProQuad™

V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)

Start: Mar 2006Est. completion: Sep 20071,027 patients

Phase 3Completed

NCT00127010 GSKMeasles, Mumps, Rubella and Chickenpox

Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases

Start: Nov 2005Est. completion: Jun 2006

Phase 3Completed

NCT00432523 MSDM-M-R™II manufactured with recombinant Human Albumin

Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)

Start: Jan 2005Est. completion: Sep 2005752 patients

Phase 3Completed

NCT00092430 MSDV221, measles, mumps, rubella and varicella

Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)

Start: Sep 2002Est. completion: Jun 20031,200 patients

Phase 3Completed

NCT00985166 MSDProQuad

A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)

Start: Aug 2000Est. completion: May 2003801 patients

Phase 3Completed

NCT00984295 MSDMeasles, Mumps, Rubella and Varicella

Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines

Start: Jun 2000Est. completion: Dec 20011,913 patients

Phase 3Completed

NCT00985153 MSDMeasles, Mumps, Rubella and Varicella

Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)

Start: Mar 2000Est. completion: May 20013,927 patients

Phase 3Completed

NCT00092391 MSDComparator: M-M-R

A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)

Start: Feb 1999Est. completion: Jul 20011,997 patients

Phase 3Completed

NCT00975507 MSDMeasles, Mumps, Rubella and Varicella

ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)

Start: Mar 1998Est. completion: Jun 1999480 patients

Phase 3Completed

NCT00892775 GSKPriorix-Tetra

Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds

Start: Jun 2009Est. completion: Dec 2010501 patients

Phase 2Completed

NCT00891007 Bavarian NordicMVA-mBN85B

Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years

Start: Jun 2009Est. completion: Aug 201090 patients

Phase 2Completed

NCT00109278 MSDV205C, measles, mumps, and rubella virus vaccine live

A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)

Start: Oct 2004Est. completion: May 20051,100 patients

Phase 2Completed

NCT00092404 MSDmeasles, mumps, and rubella virus vaccine live

Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)

Start: Dec 2001Est. completion: Jun 20051,210 patients

Phase 2Completed

NCT00986232 MSDMeasles, Mumps, Rubella and Varicella

ProQuad Dose Selection Study (V221-011)(COMPLETED)

Start: Apr 1999Est. completion: Sep 20001,551 patients

Phase 2Completed

NCT00258726 Allergy TherapeuticsMMR-II

Immune Responses to Two Dose Varivax +/- MMR-II

Start: Oct 2005Est. completion: Jul 2007105 patients

Phase 1/2Terminated

NCT05592756 BiocorpSecondary Attack Rate Measles Vaccine In Second Situation Contacts Cases Confirmed

Secondary Attack Rate Measles Vaccine In Second Situation Contacts Cases Confirmed

Start: Apr 2020Est. completion: Mar 20222,964 patients

N/ACompleted

NCT02058927 Allergy TherapeuticsMeasles vaccine

Immune Reconstitution to Measles Virus of HIV Infected Children in Zambia

Start: May 2011Est. completion: Feb 2012203 patients

N/ACompleted

NCT00962819 MSDMMR vaccine

Measles, Mumps, and Rubella (MMR) Immunity in College Students

Start: Mar 2010Est. completion: Dec 201274 patients

N/ACompleted

NCT02712203 GSKMMR vaccine / MMRV vaccine

MMR and MMRV Vaccines: Effect of Age at First Dose on Safety and Immunogenicity of the Measles Component.

Start: Jul 2004Est. completion: Dec 20165,808 patients

N/AUnknown

NCT00138255 Allergy TherapeuticsResponses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines

Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines

Start: Jun 2004Est. completion: Jun 200532 patients

N/ATerminated

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

33 late-stage (Phase 3) programs, potential near-term approvals

11 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.